GMDAQ — Gamida Cell Share News
0.000.00%
Last trade - 00:00- $2.62m
- $35.61m
- $1.78m
Brief: Gamida Cell Announces FDA Acceptance Of Biologics License Application For Omidubicel With Priority Review
Gamida up as FDA grants priority review to blood cancer therapy
Brief: Gamida Cell Appoints Ivan Borrello To Board Of Directors
Brief: Gamida Cell Completes Rolling Biologics License Application Submission To The FDA For Omidubicel
Brief: Gamida Cell Reports Opening to Enrollment of Phase 1/2 Study of NK Cell Therapy Candidate GDA-201
Gamida Cell Ltd reports results for the quarter ended in March - Earnings Summary
Gamida Cell Ltd expected to post a loss of 34 cents a share - Earnings Preview
Gamida Cell Ltd expected to post a loss of 34 cents a share - Earnings Preview
Brief: Gamida Cell Presents Updated One-Year Post-Transplant Follow Up Data From Phase 3 Study Of Omidubicel
U.S. STOCKS ON THE MOVE-Polaris Inc, Invesco Ltd, Corning Inc
U.S. STOCKS ON THE MOVE-Twitter Inc, Block Inc, 3M Co
Gamida jumps on U.S. FDA clearance for cancer therapy study
Brief: Gamida Cell Announces FDA Clearance Of IND And Removal Of Clinical Hold For NK Cell Therapy Candidate Gda-201
Gamida Cell Ltd reports results for the quarter ended in December - Earnings Summary
Brief: Gamida Cell Reports Fourth Quarter, Provides Company Update
Gamida Cell Ltd expected to post a loss of 40 cents a share - Earnings Preview
Gamida Cell Ltd expected to post a loss of 40 cents a share - Earnings Preview
Gamida up on marketing application for blood cancer therapy
Brief: Gamida Cell Initiates Rolling Submission Of Biologics License Application For Omidubicel